Ireland-based Covidien has launched its EverFlex self-expanding peripheral stent with Entrust Delivery System in Australia and New Zealand.
Major features of the latest stent version is the new Entrust Delivery System, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device.
Epworth Hospital, Richmond, associate professor Michael Denton said: "With a lower profile, the puncture site is smaller, possibly resulting in fewer access site complications and faster ambulatory rates."
Major feature of the latest version of the stent is the new Entrust Delivery System, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device.
Covidien said that the Entrust Delivery System uses the EverFlex stent, which is used to re-open narrowed (stenotic) regions of the superficial femoral and proximal popliteal arteries, supplying blood to the legs.
Peripheral arterial disease (PAD) is a condition that is related to narrowing of these arteries, where plaque builds along lining of the arteries, blocking blood flow to the legs.
The 36-month results from the DURABILITY II trial show that even in long, complex lesions, the EverFlex stent is able to sustain patency and durability.
In addition, with the Entrust Delivery System, physicians can deploy all sizes, up to 150mm lengths of the Covidien EverFlex stent on a low 5 F profile with preserved radial force.
Covidien chief medical officer of Vascular Therapies Mark Turco said: "The design of the system is based on extensive physician feedback and procedural observation, and should allow for better performance during stent deployment."